Short Term Rating on Edwards Lifesciences Corporation (EW)

Edwards Lifesciences Corporation (EW) : 10 brokerage houses believe that Edwards Lifesciences Corporation (EW) is a Strong Buy at current levels. 2 Analyst considers the fundamentals to be worthy of a Buy recommendation. 5 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Edwards Lifesciences Corporation (EW). Zacks Investment Research suggests a Sell with a rank of 4.The median of all the 17 Wall Street Analysts endorse the stock as a Buy with a rating of 1.68.

Edwards Lifesciences Corporation (EW) : Average target price received by Edwards Lifesciences Corporation (EW) is $117.14 with an expected standard deviation of $9.26. The most aggressive target on the stock is $132, whereas the most downbeat target is $100. 14 financial analysts are currently covering the stock.

For the current week, the company shares have a recommendation consensus of Buy.


Edwards Lifesciences Corporation (NYSE:EW): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $104.95 and $104.62 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $106.56. The buying momentum continued till the end and the stock did not give up its gains. It closed at $106.27, notching a gain of 1.71% for the day. The total traded volume was 1,912,498 . The stock had closed at $104.48 on the previous day.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patients diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patients cardiovascular function in the hospital setting. Patients in the hospital setting, including high-risk patients in the operating room or intensive care unit, are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.